| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PHLDA2 |
| Uniprot No | Q53GA4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-152aa |
| 氨基酸序列 | MKSPDEVLREGELEKRSDSLFQLWKKKRGVLTSDRLSLFPASPRARPKELRFHSILKVDCVERTGKYVYFTIVTTDHKEIDFRCAGESCWNAAIALALIDFQNRRALQDFRSRQERTAPAAPAEDAVAAAAAAPSEPSEPSRPSPQPKPRTP |
| 预测分子量 | 44.1kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PHLDA2重组蛋白的3篇代表性文献的简化信息(注：文献标题和作者为模拟示例，实际引用请以真实数据库检索结果为准)：
1. **标题**：*PHLDA2 regulates apoptosis through interaction with AKT in placental development*
**作者**：K. Okada et al.
**摘要**：研究利用重组PHLDA2蛋白揭示了其在胎盘细胞凋亡中的作用，表明PHLDA2通过抑制AKT磷酸化促进细胞死亡，可能与胎儿生长受限相关。
2. **标题**：*Overexpression of recombinant PHLDA2 enhances chemosensitivity in hepatocellular carcinoma*
**作者**：Y. Wang et al.
**摘要**：通过体外表达PHLDA2重组蛋白，发现其能增强肝癌细胞对化疗药物的敏感性，机制涉及下调抗凋亡蛋白Bcl-2的表达。
3. **标题**：*PHLDA2 as a potential tumor biomarker: Expression profiling in breast cancer via recombinant protein-based assays*
**作者**：H. Takeda et al.
**摘要**：开发了基于重组PHLDA2蛋白的检测方法，发现其在乳腺癌组织中高表达，并与患者预后不良显著相关，提示其作为诊断标志物的潜力。
如需具体文献，建议在PubMed或Web of Science中检索“PHLDA2 recombinant protein”或结合研究领域关键词(如“cancer”“apoptosis”)筛选。
**Background of PHLDA2 Recombinant Protein**
PHLDA2 (Pleckstrin Homology-Like Domain Family A Member 2), also known as TSSC3. is a maternally expressed imprinted gene located on human chromosome 11p15.5. It encodes a nuclear protein involved in regulating apoptosis, cell proliferation, and differentiation. PHLDA2 is predominantly expressed during embryonic development, particularly in the placenta, and plays a critical role in fetal growth regulation. Dysregulation of PHLDA2 has been linked to intrauterine growth restriction (IUGR) and Beckwith-Wiedemann syndrome (BWS), a congenital disorder associated with overgrowth and cancer predisposition.
The PHLDA2 protein contains a pleckstrin homology-like domain, which facilitates interactions with lipids or proteins, influencing signaling pathways such as the PI3K/AKT and p53 networks. Its overexpression has been shown to promote apoptosis and inhibit cell proliferation, suggesting a tumor-suppressive role in certain contexts. However, conflicting studies indicate pro-oncogenic effects in specific cancers, highlighting its context-dependent functionality.
Recombinant PHLDA2 protein is produced using genetic engineering techniques, often in *E. coli* or mammalian expression systems, to ensure high purity and biological activity. This engineered protein serves as a vital tool for studying PHLDA2's molecular mechanisms, including its role in developmental disorders, cancer biology, and metabolic regulation. Researchers utilize it in *in vitro* assays, antibody development, and functional studies to explore therapeutic targeting opportunities.
Given its dual roles in growth regulation and disease, PHLDA2 recombinant protein remains a focal point for understanding epigenetic regulation, imprinting disorders, and cancer progression, offering potential avenues for diagnostics and targeted therapies.
×
